JP2010511663A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010511663A5 JP2010511663A5 JP2009539724A JP2009539724A JP2010511663A5 JP 2010511663 A5 JP2010511663 A5 JP 2010511663A5 JP 2009539724 A JP2009539724 A JP 2009539724A JP 2009539724 A JP2009539724 A JP 2009539724A JP 2010511663 A5 JP2010511663 A5 JP 2010511663A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- mixture obtained
- compound according
- wetting agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 9
- 239000000314 lubricant Substances 0.000 claims 7
- 239000000080 wetting agent Substances 0.000 claims 7
- 239000004480 active ingredient Substances 0.000 claims 6
- 239000011230 binding agent Substances 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims 6
- 206010062207 Mycobacterial infection Diseases 0.000 claims 5
- 208000027531 mycobacterial infectious disease Diseases 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 3
- 239000007884 disintegrant Substances 0.000 claims 3
- 239000011248 coating agent Substances 0.000 claims 2
- 238000000576 coating method Methods 0.000 claims 2
- 238000007580 dry-mixing Methods 0.000 claims 2
- 238000005469 granulation Methods 0.000 claims 2
- 230000003179 granulation Effects 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 238000002156 mixing Methods 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 238000005507 spraying Methods 0.000 claims 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 1
- 229920002261 Corn starch Polymers 0.000 claims 1
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 229920001213 Polysorbate 20 Polymers 0.000 claims 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000002585 base Substances 0.000 claims 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims 1
- 239000008120 corn starch Substances 0.000 claims 1
- 229960001681 croscarmellose sodium Drugs 0.000 claims 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 239000001530 fumaric acid Substances 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 229960001021 lactose monohydrate Drugs 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 1
- 229940068977 polysorbate 20 Drugs 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000008247 solid mixture Substances 0.000 claims 1
- -1 sorbitan fatty acid ester Chemical class 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06125443 | 2006-12-05 | ||
| PCT/EP2007/063186 WO2008068231A1 (en) | 2006-12-05 | 2007-12-03 | Fumarate salt of (alpha s, beta r)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014191134A Division JP5894239B2 (ja) | 2006-12-05 | 2014-09-19 | （アルファｓ，ベータｒ）−６−ブロモ−アルファ−［２−（ジメチルアミノ）エチル］−２−メトキシ−アルファ−１−ナフタレニル−ベータ−フェニル−３−キノリンエタノールのフマル酸塩 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010511663A JP2010511663A (ja) | 2010-04-15 |
| JP2010511663A5 true JP2010511663A5 (enExample) | 2010-10-21 |
Family
ID=37983588
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009539724A Pending JP2010511663A (ja) | 2006-12-05 | 2007-12-03 | （アルファｓ，ベータｒ）−６−ブロモ−アルファ−［２−（ジメチルアミノ）エチル］−２−メトキシ−アルファ−１−ナフタレニル−ベータ−フェニル−３−キノリンエタノールのフマル酸塩 |
| JP2014191134A Active JP5894239B2 (ja) | 2006-12-05 | 2014-09-19 | （アルファｓ，ベータｒ）−６−ブロモ−アルファ−［２−（ジメチルアミノ）エチル］−２−メトキシ−アルファ−１−ナフタレニル−ベータ−フェニル−３−キノリンエタノールのフマル酸塩 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014191134A Active JP5894239B2 (ja) | 2006-12-05 | 2014-09-19 | （アルファｓ，ベータｒ）−６−ブロモ−アルファ−［２−（ジメチルアミノ）エチル］−２−メトキシ−アルファ−１−ナフタレニル−ベータ−フェニル−３−キノリンエタノールのフマル酸塩 |
Country Status (34)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120010216A1 (en) * | 2010-07-06 | 2012-01-12 | Brown Arthur M | Pharmaceutical compositions containing vanoxerine |
| CZ2014708A3 (cs) | 2014-10-16 | 2016-04-27 | Zentiva, K.S. | Soli Bedaquilinu |
| FI3250182T3 (fi) * | 2015-01-27 | 2023-06-28 | Janssen Pharmaceutica Nv | Dispergoituvia koostumuksia |
| CN106279017A (zh) * | 2015-05-21 | 2017-01-04 | 重庆圣华曦药业股份有限公司 | 贝达喹啉晶型、组合物及其制备方法 |
| CZ2015391A3 (cs) | 2015-06-09 | 2016-12-21 | Zentiva, K.S. | Sůl bedaquilinu s kyselinou citronovou |
| RU2018111482A (ru) * | 2015-10-20 | 2019-11-21 | Чжэцзян Хисунь Фармасьютикал Ко., Лтд. | Кристаллические формы бедаквилин фумарата и способы их получения |
| DK3971177T3 (da) * | 2016-07-20 | 2024-07-15 | Novartis Ag | Aminopyridin-derivater og anvendelse deraf som selektive ALK-2-inhibitorer |
| CN106316943A (zh) * | 2016-07-27 | 2017-01-11 | 重庆华邦制药有限公司 | 富马酸贝达喹啉晶型化合物的精制方法 |
| SI3943070T1 (sl) | 2017-07-14 | 2024-03-29 | Janssen Pharmaceutica Nv, | Dolgo delujoče formulacije bedakilina |
| JP7654544B2 (ja) * | 2018-12-13 | 2025-04-01 | マンカインド コーポレイション | ベダキリンの組成物、それらを含む組み合わせ、それらを調製するための方法、それらを含む使用及び治療方法 |
| WO2020144197A1 (en) | 2019-01-09 | 2020-07-16 | Janssen Pharmaceutica Nv | Combination in the treatment of nontuberculous mycobacterial diseases |
| WO2020161743A1 (en) * | 2019-02-08 | 2020-08-13 | Mylan Laboratories Limited | Process for the preparation of bedaquiline fumarate |
| KR102303635B1 (ko) * | 2020-07-01 | 2021-09-17 | 동아에스티 주식회사 | (1r,2s)-1-(6-브로모-2-메톡시퀴놀린-3-일)-4-디메틸아미노-2-(1-나프틸)-1-페닐-부탄-2-올 및 이의 약제학적으로 허용 가능한 염의 제조방법 |
| CN111888477B (zh) * | 2020-09-15 | 2023-03-07 | 北京福元医药股份有限公司 | 一种贝达喹啉药物制剂 |
| KR20230107275A (ko) | 2020-11-12 | 2023-07-14 | 얀센 파마슈티카 엔.브이. | 비결핵성 마이코박테리아 질환의 치료에서 베다퀼린, 에탐부톨 및 마크롤라이드의 조합물 |
| US11793808B2 (en) | 2021-02-22 | 2023-10-24 | Mannkind Corp. | Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them |
| WO2023150747A1 (en) | 2022-02-07 | 2023-08-10 | Insmed Incorporated | Dry powder compositions of bedaquiline and salts and methods of use thereof |
| WO2023232838A1 (en) | 2022-05-31 | 2023-12-07 | Janssen Pharmaceutica Nv | Bedaquiline for use in the treatment of leprosy |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3237575A1 (de) * | 1982-10-09 | 1984-04-12 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue orale mopidamolformen |
| GB8824392D0 (en) * | 1988-10-18 | 1988-11-23 | Ciba Geigy Ag | Dispersible formulation |
| TW355683B (en) * | 1994-02-17 | 1999-04-11 | Janssen Pharmaceutica Nv | Composition containing micronized nebivolol |
| WO1998018326A1 (en) | 1996-10-28 | 1998-05-07 | Department Of The Army, U.S. Government | Compounds, compositions and methods for treating antibiotic-resistant infections |
| IL122026A0 (en) * | 1996-10-30 | 1998-03-10 | Lilly Co Eli | Improvements in or relating to the prophylaxis of breast cancer |
| US6819464B2 (en) * | 2002-06-19 | 2004-11-16 | Seiko Epson Corporation | Optical modulator, optical device and projector |
| DK2301544T3 (da) * | 2002-07-25 | 2013-01-02 | Janssen Pharmaceutica Nv | Quinolinderivater som mellemprodukter til mykobakterielle inhibitorer |
| WO2004050068A1 (en) * | 2002-11-29 | 2004-06-17 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base |
| EP1753427B1 (en) * | 2004-05-28 | 2008-04-02 | Janssen Pharmaceutica N.V. | Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases |
| WO2006024667A1 (en) * | 2004-09-02 | 2006-03-09 | Janssen Pharmaceutica N.V. | Furamate of 4-( (4-( (4- (2-cyanoethenyl) -2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile |
| JP2006182755A (ja) * | 2004-12-24 | 2006-07-13 | Janssen Pharmaceut Nv | 潜伏性結核の処置 |
-
2007
- 2007-03-12 UA UAA200904218A patent/UA97813C2/uk unknown
- 2007-12-02 JO JO2007511A patent/JO2973B1/en active
- 2007-12-03 EA EA200970532A patent/EA017091B9/ru active Protection Beyond IP Right Term
- 2007-12-03 CN CN201510368829.1A patent/CN105012303A/zh active Pending
- 2007-12-03 NZ NZ576485A patent/NZ576485A/en unknown
- 2007-12-03 PL PL07847697T patent/PL2086940T3/pl unknown
- 2007-12-03 MX MX2009005909A patent/MX2009005909A/es active IP Right Grant
- 2007-12-03 DK DK07847697.5T patent/DK2086940T3/da active
- 2007-12-03 CL CL200703472A patent/CL2007003472A1/es unknown
- 2007-12-03 EP EP07847697A patent/EP2086940B1/en active Active
- 2007-12-03 AU AU2007328945A patent/AU2007328945B2/en active Active
- 2007-12-03 ME MEP-2012-95A patent/ME01456B/me unknown
- 2007-12-03 CN CNA2007800448088A patent/CN101547904A/zh active Pending
- 2007-12-03 PT PT07847697T patent/PT2086940E/pt unknown
- 2007-12-03 SI SI200730984T patent/SI2086940T1/sl unknown
- 2007-12-03 KR KR1020097011043A patent/KR101514700B1/ko active Active
- 2007-12-03 ES ES07847697T patent/ES2387923T3/es active Active
- 2007-12-03 WO PCT/EP2007/063186 patent/WO2008068231A1/en not_active Ceased
- 2007-12-03 CA CA2668512A patent/CA2668512C/en active Active
- 2007-12-03 RS RS20120336A patent/RS52408B/sr unknown
- 2007-12-03 MY MYPI20092284A patent/MY148844A/en unknown
- 2007-12-03 BR BRPI0719693-8A2A patent/BRPI0719693A2/pt not_active Application Discontinuation
- 2007-12-03 US US12/515,986 patent/US8546428B2/en active Active
- 2007-12-03 AP AP2009004870A patent/AP2498A/xx active
- 2007-12-03 JP JP2009539724A patent/JP2010511663A/ja active Pending
- 2007-12-03 HR HRP20120639TT patent/HRP20120639T1/hr unknown
- 2007-12-04 TW TW096146000A patent/TWI417098B/zh active
- 2007-12-05 AR ARP070105442A patent/AR064149A1/es not_active Application Discontinuation
- 2007-12-05 UY UY30762A patent/UY30762A1/es active IP Right Grant
- 2007-12-05 PE PE2007001719A patent/PE20081350A1/es active IP Right Grant
-
2009
- 2009-06-02 IL IL199077A patent/IL199077A/en active IP Right Grant
- 2009-06-04 ZA ZA2009/03907A patent/ZA200903907B/en unknown
- 2009-07-06 NO NO20092535A patent/NO342773B1/no unknown
-
2012
- 2012-08-13 CY CY20121100734T patent/CY1113594T1/el unknown
-
2014
- 2014-09-19 JP JP2014191134A patent/JP5894239B2/ja active Active
-
2016
- 2016-03-04 HK HK16102481.4A patent/HK1214513A1/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010511663A5 (enExample) | ||
| CN1988891B (zh) | 包衣片制剂和方法 | |
| CN102548544B (zh) | 同时具有速效特性和长效特性的药物组合物 | |
| TWI583384B (zh) | 包含４－胺基－５－氟－３－［６－（４－甲基哌嗪－１－基）－１ｈ－苯并咪唑－２－基］－１ｈ－喹啉－２－酮乳酸鹽單水合物之醫藥組合物 | |
| HRP20120639T1 (hr) | Fumaratna sol (alfa s, beta r)-6-bromo-alfa-[2-(dimetilamino)etil]-2-metoksi-alfa-1-naftalenil-beta-fenil-3-kinolinetanola | |
| JP2009545560A5 (enExample) | ||
| CN105998017A (zh) | 具有提高的稳定性的包含氨氯地平和氯沙坦的固体药物组合物 | |
| HU202102B (en) | Process for producing oral pharmaceutical compositions with controlled release of the active components | |
| WO2013020416A1 (zh) | 伊伐布雷定或其可药用盐的缓释制剂 | |
| JP2011502140A (ja) | トルテロジンの制御放出型医薬組成物 | |
| US8563035B2 (en) | Oral tablet compositions of dexlansoprazole | |
| JP5211040B2 (ja) | ピリジルメチルスルフィニルベンズイミダゾールのための経口速放医薬製剤 | |
| TW201035089A (en) | Pharmaceutical composition | |
| WO2014006636A2 (en) | Stable compositions of fesoterodine | |
| EP2685966A1 (en) | Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor | |
| WO2014096982A1 (en) | Stable pharmaceutical compositions of saxagliptin or salts thereof | |
| WO2011161689A1 (en) | Imatinib mesilate pharmaceutical tablet | |
| JP2015503555A (ja) | ボセンタン制御放出性経口製剤 | |
| WO2011000518A1 (en) | Pharmaceutical composition comprising desloratadine | |
| US20120301548A1 (en) | Oral complex composition comprising pseudoephedrine and levocetirizine | |
| WO2014096983A1 (en) | Stable pharmaceutical compositions of saxagliptin or salts thereof | |
| JP2010516712A5 (enExample) | ||
| EP2803353B1 (en) | Compositions of Imatinib | |
| EP2384747A2 (en) | Oral Tablet Compositions Of Dexlansoprazole | |
| JP2013536832A (ja) | ミルナシプランの制御放出医薬組成物 |